CDK4 and breast carcinoma: Specifically, the profiling of a breast cancer cell line panel with palbociclib, a selective CDK4/6 inhibitor, demonstrated that CDK4/6 inhibitors are exquisitely effective at inhibiting the growth of ER+ cells [15].